736 related articles for article (PubMed ID: 19837762)
1. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
2. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
[TBL] [Abstract][Full Text] [Related]
3. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
4. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
6. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
7. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
8. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
Rizvi SN; Visser OJ; Vosjan MJ; van Lingen A; Hoekstra OS; Zijlstra JM; Huijgens PC; van Dongen GA; Lubberink M
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):512-20. PubMed ID: 22218876
[TBL] [Abstract][Full Text] [Related]
10. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
[TBL] [Abstract][Full Text] [Related]
11. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.
Heuveling DA; de Bree R; Vugts DJ; Huisman MC; Giovannoni L; Hoekstra OS; Leemans CR; Neri D; van Dongen GA
J Nucl Med; 2013 Mar; 54(3):397-401. PubMed ID: 23334725
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
13. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
14. Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.
Jauw YWS; Heijtel DF; Zijlstra JM; Hoekstra OS; de Vet HCW; Vugts DJ; Verheul HM; Boellaard R; Zweegman S; van Dongen GAMS; der Houven van Oordt CWM; Lammertsma AA; Huisman MC
Mol Imaging Biol; 2018 Dec; 20(6):1025-1034. PubMed ID: 29713958
[TBL] [Abstract][Full Text] [Related]
15. Phase I/IIa PET imaging study with
Joraku A; Hatano K; Kawai K; Kandori S; Kojima T; Fukumitsu N; Isobe T; Mori Y; Sakata M; Hara T; Nasu K; Minami M; Iizumi Y; Nishiyama H
Ann Nucl Med; 2019 Feb; 33(2):119-127. PubMed ID: 30406361
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [
Lumen D; Vugts D; Chomet M; Imlimthan S; Sarparanta M; Vos R; Schreurs M; Verlaan M; Lang PA; Hippeläinen E; Beaino W; Windhorst AD; Airaksinen AJ
Bioconjug Chem; 2022 May; 33(5):956-968. PubMed ID: 35442642
[TBL] [Abstract][Full Text] [Related]
17. Phase I study to assess safety, biodistribution and radiation dosimetry for
Merkx RIJ; Lobeek D; Konijnenberg M; Jiménez-Franco LD; Kluge A; Oosterwijk E; Mulders PFA; Rijpkema M
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3277-3285. PubMed ID: 33651116
[TBL] [Abstract][Full Text] [Related]
18. (S)-4-(3-18F-fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging--dosimetry.
Smolarz K; Krause BJ; Graner FP; Wagner FM; Hultsch C; Bacher-Stier C; Sparks RB; Ramsay S; Fels LM; Dinkelborg LM; Schwaiger M
J Nucl Med; 2013 Jun; 54(6):861-6. PubMed ID: 23568366
[TBL] [Abstract][Full Text] [Related]
19. Validation of simplified dosimetry approaches in ⁸⁹Zr-PET/CT: the use of manual versus semi-automatic delineation methods to estimate organ absorbed doses.
Makris NE; van Velden FH; Huisman MC; Menke CW; Lammertsma AA; Boellaard R
Med Phys; 2014 Oct; 41(10):102503. PubMed ID: 25281978
[TBL] [Abstract][Full Text] [Related]
20. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
